3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
40
Endocrine
40
Gastrointestinal
4
CNS
4
Sarcoma
1
Dermatologic
1
Conditions
Sarcoma, Synovial
1
Recurrence
1
Pheochromocytoma
1
Paraganglioma
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Meningioma
1
Medulloblastoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Quality of Life
2
Fluorodeoxyglucose F18
2
tivozanib
1
tislelizumab
1
surufatinib
1
romidepsin
1
repotrectinib
1
olaparib
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
atezolizumab
1
amino-acid, glucose, and electrolyte solution
1
alectinib
1
Surveys and Questionnaires
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Patient Reported Outcome Measures
1
PM 01183
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Lactones
1
Irinotecan
1
Interleukin-2
1
Immunotherapy
1
FAPI-46
1
Drug Therapy
1
Depsipeptides
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
lutetium Lu 177 dotatate
×
Sarcoma
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled